Date: 2017-09-28
Type of
information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: Bluebird bio (USA - MA)
Product: bb21217
Action
mechanism:
- cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy. bb2121 is a chimeric antigen receptor T cell (CAR T) therapy targeting B cell maturation antigen (BCMA). Bluebird bio is developing bb2121 in collaboration with Celgene.
Disease: relapsed/refractory multiple myeloma
Therapeutic
area: Cancer - Oncology
Country: USA
Trial
details:
- The primary objective of the CRB-402 study is to evaluate the maximum tolerated dose of bb21217 and determine the recommended Phase 2 dose. The secondary objective is preliminary efficacy data, measured using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma. The first portion of the study includes a dose-escalation phase in which cohorts of patients will receive ascending doses of bb21217 to determine the maximum tolerated dose and establish a recommended Phase 2 dose. The second portion of the study is a dose expansion phase where patients will receive bb21217 to further evaluate the safety, tolerability and clinical activity at the recommended Phase 2 dose. (NCT03274219)
Latest
news:
- • On September 28, 2017, bluebird bio announced the treatment of the first patient with relapsed/refractory multiple myeloma in a Phase 1 study of bb21217. bb21217 is an investigational chimeric antigen receptor T cell (CAR T) therapy targeting B cell maturation antigen (BCMA).
“
Is
general: Yes
